Over the past decade, the incidence of Clostridium difficile infection (CDI) has steadily increased in hospitalized children [1, 2] . From 2001 to 2006, both the number of admissions due to CDI and the number of hospital-acquired cases increased, from 2.4 to 4.0 per 1000 admissions and 4.4 to 6.5 per 10 000 patient-days, respectively, at 22 children's hospitals in the United States [3] . Increasing numbers of pediatric hospitalizations with CDI (from 7.24 to 12.80 per 10 000 hospitalizations) were also reported from 1997 to 2006 [4] .
Pediatric CDI has very recently been associated with increased mortality, longer hospital stay, and higher costs among hospitalized children [5] . Recent guidelines emphasize the importance of CDI surveillance using standardized case definitions to understand the magnitude of and reasons for the changing epidemiology of CDI, to improve comparability between institutions, and to optimize infection control and prevention efforts [6, 7] . Standardized surveillance is of additional importance as the Center for Medicare and Medicaid Services mandated US hospitals to reduce their CDI rates by 30% in the next 5 years [8] . The proposed case definitions are based on disease onset respective to hospitalization, as well as recent exposures to healthcare facilities [7] . Traditionally, healthcare facility-associated disease (HA-CDI) is considered when CDI symptom onset occurs during hospitalization (48 hours after admission), or up to 4 weeks after discharge. If symptom onset appears between 4 and 12 weeks after discharge, CDI is classified as "indeterminate" disease. It is recommended that these need not be differentiated from community-associated CDI (CA-CDI; defined as symptom onset in the community or during the first 48 hours of admission and no prior admission to a healthcare facility in the last 12 weeks) for surveillance purposes [7] .
The aim of this study was to distinguish risk factors and clinical outcomes of children with HA-CDI and CA-CDI, and to clarify if children classified as having indeterminate disease have similar risk profiles as children with HA-CDI or CA-CDI, in order to allocate them correctly and to guide decisions regarding future surveillance strategies in this "at risk" population.
METHODS

Design and Ethical Issues
This retrospective, observational cohort study was approved by the Johns Hopkins University School of Medicine institutional review board, and informed consent was waived.
Setting
The Johns Hopkins Children's Center is a university-affiliated tertiary care center with 220 beds and an average of 6500 admissions annually that serves the Baltimore-Washington area and surrounding region.
Patients and Data Collection
All patients aged 1-21 years hospitalized at the Johns Hopkins Children's Center from July 2003 to July 2012 were eligible for inclusion in this study. Only patients with clinical symptoms consistent with CDI (ie, diarrhea defined as ≥3 loose stools/day alone or in combination with other gastrointestinal symptoms as abdominal pain or emesis), confirmatory laboratory testing, and no other identified causes of diarrhea [6] , as well as clinical confirmation of the diagnosis by the treating physician and respective initiation of treatment, were eligible for inclusion. (Routine diagnostics for children with diarrhea at our institution include the identification of Salmonella, Shigella, Campylobacter, Yersinia, and enterohemorrhagic Escherichia coli 0157; rotavirus is only screened for in infants based on current vaccination policies and norovirus is screened for if symptoms are suggestive.) Infants <1 year of age were excluded because of difficulties distinguishing colonization and infection in this age group. Microbiologic data were queried from the hospital's electronic database to identify inpatients with positive test results for toxin-producing C. difficile. The main outcome of interest was the development of CDI, whether CA-CDI, HA-CDI, or indeterminate CDI, as described below. Patient's demographics, baseline characteristics, comorbid conditions, and prior exposure to healthcare facilities were obtained by electronic and paper medical records review, including records on outpatient visits in the same institution. In addition, exposure to antibiotics, receipt of chemotherapy, use of gastric acid-suppressive agents, receipt of narcotics and prior surgeries, and prior history of CDI were captured. Exposures were collected if they occurred during the 30 days prior to CDI onset, except for chemotherapy, which was captured during a time frame of 6 months prior to CDI onset. Information regarding clinical course and outcome of CDI was recorded.
Definitions and Categorization of Patients
Cases were defined using standard definitions [7] . Healthcare facility-onset, healthcare facility-associated CDI (HO-HCFA CDI) was defined as CDI symptom onset >48 hours after admission. Community-onset, healthcare facility-associated CDI (CO-HCFA CDI) was defined as symptom onset in the community or ≤48 hours after admission, provided that symptom onset was <4 weeks after the last discharge from a healthcare facility. Community-associated CDI (CA-CDI) was defined as symptom onset in the community or ≤48 hours after admission, provided that symptom onset was >12 weeks after the last discharge from a healthcare facility. Indeterminate CDI was defined as CDI not fitting any of the above criteria for an exposure setting, that is, CDI symptom onset occurred between 4 and 12 weeks from a hospital dismissal. HO-HCFA CDI and CO-HCFA CDI were defined as healthcare facility-associated CDI (HA-CDI).
Recurrent CDI was defined as an episode of CDI that occurred within 8 weeks after the onset of a previous episode, provided that CDI symptoms from the earlier episode resolved, with or without therapy.
Microbiology
Up to June 2009, the microbiology laboratory used a 2-step algorithm to identify C. difficile [6] . First, stool specimens were screened for C. difficile glutamate dehydrogenase antigen and then screen-positive specimens underwent cell culture cytotoxicity assay. Beginning in June 2009 through January 2010, the toxin A/B test was replaced with polymerase chain reaction (PCR; BD GeneOhm Cdiff assay, Sparks, Maryland). Beginning in January 2010, PCR alone was used for direct detection of toxigenic C. difficile.
Statistical Analyses
The χ 2 and Fisher exact test (where appropriate) were used for comparisons of proportions. For continuous variables, the Shapiro-Wilk test was used to distinguish between normal and abnormal distributions. Normally distributed variables were analyzed using the Student t test and nonnormally distributed variables using the Mann-Whitney U test. To identify possible confounding, all variables found to be significant in univariable analyses were included in the multivariable regression models after calculating odds ratios by logistic regression. Stepwise logistic regression using stepwise forward and backward selection, as well as Akaike information criterion (AIC), were applied to identify variables independently associated with either CA-CDI or HA-CDI, and collinearity between covariates was assessed.
The Hosmer-Lemeshow goodness-of-fit test was applied to check the final models. Areas under the receiver operating characteristic (ROC) curve were calculated for the final models to evaluate discrimination. Two-sided P values <.05 were considered statistically significant. Analyses were performed using Stata statistical software, version 12.0 (Stata Corp, College Station, Texas). [7] . *Defined as the presence of a positive test result for toxigenic C. difficile in the absence of clinical symptoms.
RESULTS
From
Comparison of Indeterminate CDI With HA-CDI and CA-CDI Demographics, comorbid conditions, and risk factors of patients with indeterminate CDI, HA-CDI, and CA-CDI revealed that comorbid conditions were present in all patients with indeterminate CDI (20/20 [100%] ), but only reported in 73.7% of patients with CA-CDI (Table 1) . CA-CDI was less associated with prior exposure to antibiotics or narcotics than was indeterminate CDI.
Based on the results presented above, cases of indeterminate CDI were allocated to HA-CDI for the purposes of these analyses, as the risk profiles of indeterminate disease resembled HA-CDI more than CA-CDI. Therefore, indeterminate cases were combined with HA-CDI for subsequent analyses.
Risk Profiles of CA-CDI and HA-CDI Cases (Including Indeterminate Disease)
Patients with CA-CDI were older compared to patients with HA-CDI or indeterminate CDI. The majority (84.2%) were exposed to healthcare facilities during ambulatory care ( Table 2) . Whereas nearly all patients with HA-CDI had comorbid conditions (97.6%), no comorbidities were reported for 26.3% of patients with CA-CDI (P < .001; Table 2 ). Exposures to risk factors prior to disease onset differed significantly between the 2 groups. Whereas 76.8% of patients with HA-CDI received antibiotics 30 days before disease onset, antibiotic exposure was only reported for 42.1% of CA-CDI cases (P < .001; Table 3 ). Furthermore, patients with CA-CDI were less likely to have been exposed to antacids, in addition to surgeries, including antibiotic prophylaxis or receipt of narcotics. No major differences regarding treatment duration were noted between patients with CA-CDI and those with HA-CDI (Table 3) . However, patients with CA-CDI were more likely to suffer from recurrences (8/38 [21.1%] vs 15/164 [9.1%], P = .037) and tended to have more complications of CDI (P = .066; Table 3 ).
To identify independent risk factors for either CA-CDI or HA-CDI, we included age, presence of comorbidities, exposure to antibiotics and antacids in the last 30 days, and prior surgical procedures in the stepwise multivariable models. The presence of comorbid illness, exposure to antibiotics, and prior surgical procedures were independently associated with HA-CDI ( Table 4 ). The mean variance inflation factor for all variables included in the multivariable models was 1.13, ranging from 1.08 to 1.17, ruling out high collinearity and indicating that the selected variables were uncorrelated with the other predictor variables. The Hosmer-Lemeshow goodness-of-fit tests for the model selection by AIC was χ 2 = 2.85 (P = .943) and for the stepwise forward and backward selection was χ 2 = 1.12 (P = .772), indicating adequate model fit. The area under the ROC curve for Table 2 . the stepwise regression model was 0.866, supporting its ability to discriminate between CA-CDI and HA-CDI. To assess the impact of allocation of indeterminate cases to HA-CDI, we performed a sensitivity analysis by applying the multivariable model outlined above to the same dataset after excluding cases of indeterminate CDI and CO-HCFA CDI, and found identical results.
DISCUSSION
CDI is an emerging problem among children, and the scientific community is challenged about how to measure impact and outcomes. Not surprisingly, we found among >200 hospitalized children that those with CA-CDI are less likely to have comorbid conditions or to have been exposed to either antibiotics or surgical procedures 30 days prior to disease onset when compared to children with HA-CDI. However, we found that hospitalized children with CA-CDI trended toward more severe complications, such as septic shock (related to CDI) and toxic megacolon and had a higher proportion of recurrences than those with HA-CDI. Interestingly, risk profiles of children with indeterminate CDI, classified as disease onset in the community 4-12 weeks from a hospital discharge, are more alike those identified for healthcare-associated disease, suggesting that these cases should be allocated to HA-CDI rather than CA-CDI for surveillance purposes. The recommendations for surveillance of C. difficile-associated disease [7] , endorsed by the Society for Healthcare Epidemiology of America/Infectious Diseases Society of America guidelines [6] , propose reporting CO-HCFA CDI, in addition to HO-HCFA CDI, as healthcare facility associated. This is based on the assumption that transmission in the healthcare facility is responsible for delayed-onset CDI. Several prior studies support this hypothesis by demonstrating the increased risk for CDI after hospitalization [9] , and among cancer outpatients, the risk for CDI was strongly related to inpatient exposures [10] . New exposure to C. difficile increases the risk of subsequent infection [7] . As healthcare facility exposure and length of hospital stay are associated with an increased risk of C. difficile colonization [11, 12] , and data collected in children suggest person-to-person transmission or contaminated environments being responsible for subsequent carriage [13] , acquisition is more likely to occur during hospital stay than after discharge. This premise underlies the established suggestion to allocate CDI occurring up to 4 weeks after discharge to HA-CDI [7] . We propose to extend this time frame based on our finding that the same triggers were identified in children with development of CDI up to 12 weeks after discharge, the lower likelihood of acquisition of C. difficile in the community, and data indicating that the incubation period exceeds 12 weeks in 13% of CDI cases-a very similar proportion as the 10% of indeterminate cases identified in our study [14] . It is noteworthy that among children with CA-CDI, 84% had contact with the healthcare system as outpatients in the 3 months prior to CDI onset. Traditionally, the risk of acquiring C. difficile as an outpatient has been regarded as very low, as contact time is short; however, further studies are needed to assess the possibility of transmission in this setting.
Exposure to antibiotics is the most important risk factor for the development of CDI in adults [15] . Among children, data on risk factors are limited and prior exposure to antibiotics has not always been reported [16] . A large retrospective study reviewed exposures over a 5-year period, and no documented antibiotic exposure was identified for 43% of pediatric patients, prior to CDI onset [17] . In our study, the majority of patients were exposed to antibiotics (70.3%). Patients with CA-CDI were, however, less likely to have been exposed than patients with HA-CDI, and almost 30% of children developed CA-CDI without having received antibiotics. A similar result, reported among an adult population in the Netherlands, identified that 13 of 31 patients (42%) with CA-CDI reported no exposure to antibiotics in the prior 6 months [18] . Exposure to surgery, narcotics, and antibiotic prophylaxis in the last 30 days prior to CDI onset were detected in up to 52% of cases in our cohort, mirroring findings of another recent study [19] , where 52% of CDI cases reported operative interventions in the 2 months prior to diagnosis.
The importance of gastric acid suppression as a risk factor for CDI has been of interest in recent years [20] . A recent study on >4000 adult patients detected a significant association between exposure to proton pump inhibitors and CDI [15] . Additionally, a meta-analysis reviewed 30 studies and identified a 2-fold increase in risk for CDI among patients who received proton pump inhibitors [21] . In 68 children, a case-control study found that exposure to proton pump inhibitors increased the risk of CDI by 4.5-fold (95% confidence interval, 1.4-to 14.4-fold) [22] . More than half of the CDI patients included in our study (56%) were exposed to gastric acid suppression, the proportions differing significantly between children with CA-CDI and HA-CDI.
As antibiotics, recent surgery, and the presence of comorbid conditions were less common in hospitalized children with CA-CDI, other factors may be more important in driving the increasing rates of CA-CDI [17, 23] . One possible explanation may be the circulation of more virulent strains in the community, which may also explain the higher proportions of complications and recurrences detected in community-associated disease in our cohort [24] . In the United States, severe cases of CDI in healthy children with no previous exposure to antibiotics due to the PCR ribotype 027 strain have been reported [24] , and this hypervirulent strain was detected in 19.4% of C. difficile toxin-positive stool samples at 2 children's hospitals [25] . A study of 8569 adults described higher colectomy rates in adults with disease onset in the community (16.5/1000 vs 4.3/1000), but strain typing was not assessed in the study [26] . This hypothesis is also underscored by the report on a new hypervirulent strain of C. difficile (PCR ribotype 078) affecting a younger population and more frequently being associated with community-associated disease in the Netherlands [27] . Information on the emergence of the hypervirulent PCR ribotype 027 in the community is, however, still lacking. Nevertheless, the increased risk of complications, and also recurrences in community-onset disease resulting in hospitalization, is an important consideration for the treating clinician.
Important limitations of this study include its conduction at a single center and its retrospective design. The setting of an academic tertiary care center may have led to a selection of patients with complicated underlying medical conditions, thus limiting generalizability to other settings. Ascertainment bias may have been introduced as this study relied on clinical records review to identify exposures to risk factors during the last 30 days prior to CDI onset. This could have led to underestimation of exposures, especially antibiotic use, in patients with CA-CDI. However, a nationally representative analysis of antibiotic prescribing in ambulatory pediatrics from 2006 to 2008 reported that antibiotics were prescribed during 21% of pediatric ambulatory visits [28] ; therefore, our finding that 42.1% of all CA-CDI patients were exposed to antibiotics prior to disease Bold P values are considered significant.
Abbreviations: AIC, Akaike information criterion (stepwise model selection); CDI, Clostridium difficile Infection; CI, confidence interval; OR, odds ratio.
onset seems reasonable. As the number of children with severe complications is small in this cohort, our finding regarding the association with CA-CDI must be interpreted with caution. Furthermore, only pediatric inpatients were included in our study, so children diagnosed with CDI not requiring hospitalization were not captured. Therefore, our study only allows for inference in pediatric inpatients and no conclusions regarding CA-CDI in general can be drawn.
In conclusion, in the setting of relevant clinical symptoms, the diagnosis of CDI should be considered in healthy children even without recent exposure to antibiotics. Additional studies need to identify stimulus for increasing rates of community-associated disease, as this trend may not be solely explained by traditional risk factors. Surprisingly, severe complications and recurrences of CDI appear to be more common in patients admitted with community-associated disease-an important consideration for the treating physician. Indeterminate CDI, classified as disease onset in the community, 4-12 weeks from a hospital dismissal should be allocated to HA-CDI rather than CA-CDI for surveillance purposes.
Notes
